Maitri Shah

Charotar University of Science and Technology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

George A. Călin

The University of Texas MD Anderson Cancer Center

Cristina Ivan

The University of Texas MD Anderson Cancer Center

Masayoshi Shimizu

Material (Belgium)

Gabriel Lopez‐Berestein

The University of Texas MD Anderson Cancer Center

Xinna Zhang

Indiana University School of Medicine

Milena S. Nicoloso

Istituti di Ricovero e Cura a Carattere Scientifico

Roxana S. Redis

Charles River Laboratories (Netherlands)

Riccardo Spizzo

Istituti di Ricovero e Cura a Carattere Scientifico

Ioana Berindan‐Neagoe

Iuliu Hațieganu University of Medicine and Pharmacy

Tina Catela Ivković

Central European Institute of Technology – Masaryk University

Cooperative Institutions

The University of Texas MD Anderson Cancer Center

163

The University of Texas Health Science Center at Houston

Baylor College of Medicine

Northwestern University

NorthShore University HealthSystem

Johns Hopkins University

University of Houston

University of Chicago

The Ohio State University

Gynecologic Oncology Group

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

MicroRNAs as therapeutic targets in human cancers

Wiley Interdisciplinary Reviews - RNA (2014)

Maitri Shah George A. Călin

MicroRNAs ( miRNAs ) are evolutionarily conserved, small, regulatory RNAs that negatively regulate gene expression. Extensive research in the last decade has implicated miRNAs as master regulators of cellular processes with essential role in cancer initiation, progression, and metastasis, making them promising therapeutic tools for cancer management. In this article, we will briefly review the structure, biogenesis, functions, and mechanism of action of these miRNAs , followed by a detailed analysis of the therapeutic potential of these miRNAs . We will focus on the strategies presently used for miRNA therapy; discuss their use and drawbacks; and the challenges and future directions for the development of miRNA ‐based therapy for human cancers. WIREs RNA 2014, 5:537–548. doi: 10.1002/wrna.1229 This article is categorized under: RNA in Disease and Development > RNA in Disease RNA in Disease and Development > RNA in Development

Human disease

10.1002/wrna.1229

Cite

Citations (91)

PERCUTANEOUS CORONARY INTERVENTION OUTCOMES IN PATIENTS WITH LIVER CIRRHOSIS A META ANALYSIS

Journal of the American College of Cardiology (2023)

Harshwardhan Khandait Vikash Jaiswal Abhigan Babu Shrestha Alisson Iturburu Maitri Shah

10.1016/s0735-1097(23)01424-9

Cite

Citations (0)

HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts

Cell Death and Differentiation (2013)

Jana Ferdin Naohiro Nishida Xue Wu Milena S. Nicoloso Maitri Shah

Hypoxia

10.1038/cdd.2013.119

Cite

Citations (98)

Supplementary Figures 1-12 from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment

Masato Nishimura Eunjung Jung Maitri Shah Chunhua Lu Riccardo Spizzo

<p>Supplementary Figures 1-12 - PDF file 897K, Relative expression of miR-520d-3p (miR-520d) and miR-520d-5p (miR-520d*) in ovarian cancer cell lines (Figure S1), Kaplan-Meier curves representing the percent progression-free survival in patients with ovarian cancer based on miR-520d-3p median expression levels (Figure S2), miR-520d-5p does not target EphA2 (Figure S3), miR-520d-3p and EphA2 expression levels in miR-520d-3p overexpressing stable clones (Figure S4), Effect of miR-520d-3p expression on cell proliferation (Figure S5), miR-520d-3p and EphA2 levels in xenograft models of miR-520d-3p overexpressing HeyA8 and SKOV3ip1 models (Figure S6), Efficiency of EphA2 targeting siRNAs in HeyA8 cells (Figure S7), Combination of miR-520d-3p and siRNA-EphA2 treatment shows enhanced EphA2 inhibition in vitro (Figure S8), Dose-response curve of miR-520d-3p, si-EphA2-1 and combined miR-520d-3p + si-EphA2-1 in SKOV3ip1 and HeyA8 cells (Figure S9), Treatment with anti-miR-520d-3p can restore EphA2 protein levels in a dose-dependent manner in SKOV3ip1 cells (Figure S10), Effect of combined miR-520d-3p+siEphA2-1 treatment on angiogenesis, proliferation and apoptosis in HeyA8 cells (Figure S11), and Differentially expressed coding genes in miR-520d-3p overexpressing stable clones (Figure S12)</p>

EPH receptor A2

10.1158/2159-8290.22529420.v1

Cite

Citations (0)

Feasibility Study and Demand Estimation for Ferry Service from Hazira to Alang

Lecture notes in civil engineering (2020)

Jigar K. Patel Trupal Patel Maitri Shah Mehul Patel Omkar Bidkar

Saurashtra

10.1007/978-981-15-3742-4_20

Cite

Citations (0)

Abstract 1857: Src: A novel target for chemoprevention of early stage ER- breast cancer

Cancer Research (2011)

Shalini Jain Maitri Shah Ping Li Qingfei Wang Siyuan Zhang

Abstract Selective ER modulators (SERMs) have shown significant efficacy for the prevention of ER-positive breast cancer, however, SERMs are not effective for patients whose tumors do not express ER. Therefore, novel agents are needed for prevention and intervention of high risk ER-breast cancers. The c-Src plays a pivotal role in the progression of EGFR- and HER2-dependent ER negative breast cancer. Thus, targeting Src using agents with minimal toxicity or in combination with other novel agents may prevent/intervene progression of early stage ER- breast cancer. In this study we used Saracatinib (AztraZeneca), a Src inhibitor well-tolerated in phase II clinical trials. We examined the effect of Src inhibition using Saracatinib alone or with other agents for cancer prevention using human mammary epithelial pre-malignant cell lines (MECs) and MMTV-neu mouse model. The MCF10A MECs stably overexpressing ErbB2 (10A.ErbB2 cells) form irregular (grape-like) acini in 3D culture condition. Saracatinib treatment prevents the progression of abnormal 3D acini growth as well reverses the abnormal 3D acini growth of 10A.ErbB2 cells to normal phenotype. Our reverse phase protein array data showed that Saracatinib induces the expression of cell cycle inhibitors and apoptosis related molecules, e.g. P27kip1, RAR beta, and PDCD4. Our 3D acini confocal microscopy experiment showed that it induces luminal apoptosis and suppresses cell proliferation in 10A.ErbB2 cells as detected by activated caspase-3 and ki-67 staining respectively. Next, we used MMTV-neu mouse model which develop ER negative lesions at early stage, to examine correlation between Src activation and ER negative mammary cancer progression. MMTV-neu mice mammary lesions exhibited super-activated Src which were negatively associated with estrogen receptor (ER) expression. Our preliminary data showed that Saracatinib-containing regimen inhibited MMTV-neu mice mammary lesions. Our study demonstrated that targeting Src by Saracatinib may be effective for the chemoprevention of early stage ER negative breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1857. doi:10.1158/1538-7445.AM2011-1857

HER2/neu

10.1158/1538-7445.am2011-1857

Cite

Citations (1)

Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells

International Journal of Cancer (2013)

Dhwanil Damania Hemant K. Roy Dhananja Kunte Jean Hurteau Hariharan Subramanian

Ovarian cancer ranks fifth in cancer fatalities among American women. Although curable at early stages with surgery, most women are diagnosed with symptoms of late‐stage metastatic disease. Moreover, none of the current diagnostic techniques are clinically recommended for at‐risk women as they preferentially target low‐grade tumors (which do not affect longevity) and fail to capture early signatures of more lethal serous tumors which originate in the fimbrae region of the fallopian tubes. Hence, the early detection of ovarian cancer is challenging given the current strategy. Recently, our group has developed a novel optical imaging technique, partial wave spectroscopic (PWS) microscopy, that can quantify the nanoscale macromolecular density fluctuations within biological cells via a biomarker, disorder strength ( L d ). Using the concept of field carcinogenesis, we propose a method of detecting ovarian cancer by PWS assessment of endometrial and endocervical columnar cells. The study includes 26 patients (controls = 15, cancer = 11) for endometrium and 23 (controls = 13, cancer = 10) for endocervix. Our results highlight a significant increase in L d (% fold‐increase > 50%, p ‐value < 0.05) for columnar epithelial cells obtained from cancer patients compared to controls for both endocervix and endometrium. Overall, the quantification of field carcinogenic events in the endometrium and the novel observation of its extension to the cervix are unique findings in the understanding of ovarian field carcinogenesis. We further show independent validation of the presence of cervical field carcinogenesis with micro‐RNA expression data.

Endocervix

10.1002/ijc.28122

Cite

Citations (31)

Long Non-Coding RNA Induces De Novo Myelodysplastic Syndrome through Epigenetic Regulation

Blood (2015)

Maitri Shah Valentina Pilecki Roxana S. Redis Linda Fabris Maria Ciccone

10.1182/blood.v126.23.1640.1640

Cite

Citations (1)

Supplementary Figures 1-12 from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment

Masato Nishimura Eunjung Jung Maitri Shah Chunhua Lu Riccardo Spizzo

EPH receptor A2

10.1158/2159-8290.22529420

Cite

Citations (0)

The Mix of Two Worlds: Non-Coding RNAs and Hormones

Nucleic Acid Therapeutics (2013)

Maitri Shah George A. Călin

The recent discovery of functional cell-free circulating microRNAs (miRNAs) in human body fluids has opened new avenues for the application of non-coding RNAs (ncRNAs) as noninvasive, specific and sensitive biomarkers for cancers and other human diseases. In this review, we explore the concept of circulating miRNAs as hormones, and discuss their potential functions in cellular communication and transferring of signals. We also provide a brief overview of their identification, processing, and potential functions and applications in human diseases.

Identification

10.1089/nat.2012.0375

Cite

Citations (48)